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Abstract
Neuropsychiatric lupus is a major diagnostic challenge, and a main cause of
morbidity and mortality in patients with systemic lupus erythematosus (SLE).
Magnetic resonance imaging (MRI) is, by far, the main tool for assessing the
brain in this disease. Conventional and advanced MRI techniques are used to
help establishing the diagnosis, to rule out alternative diagnoses, and recently,
to monitor the evolution of the disease. This review explores the neuroimaging
findings in SLE, including the recent advances in new MRI methods.
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Introduction
Despite the fact that the outcome of patients with systemic lupus 
erythematosus (SLE) has improved considerably over the last 
decades, neuropshychiatric involvement remains a main cause 
of morbi-mortality1,2, being responsible for up to 19% of deaths 
in SLE3,4. The real prevalence of neuropsychiatric SLE (NPSLE) 
remains unknown, with significant heterogeneity between studies, 
from 14% to 95% depending on the inclusion criteria; an average of 
40–50% is probably widely accepted5–8. Reliable methods for diag-
nosing NPSLE are also unknown, the clinical judgment remaining 
the cornerstone for differentiation of these patients9,10. Therefore, 
NPSLE represents a major diagnostic challenge, being essentially 
a diagnosis of presumption and exclusion, established after hav-
ing ruled out other possible causes such as trauma, infection, drug 
effects, epilepsy, migraine, psychiatric disorders, multiple sclerosis, 
posterior reversible encephalopathy and previous nervous system 
disorders5,6,11,12. Very recently, an algorithm based on a probability 
score was validated to determine the relationship between neu-
ropsychiatric involvement and SLE13. On the other hand, reaching 
the correct diagnosis of NPSLE is critical in terms of therapeutic 
decisions and outcome.
According to 1999 American College of Rheumatology (ACR) Case 
Definitions for NPSLE, 19 neuropsychiatric syndromes are defined, 
divided into 12 central and 7 peripheral14. The central ones are fur-
ther divided into neurological (aseptic meningitis, cerebrovascular 
disease, demyelinating syndrome, headache including migraine and 
benign intracranial hypertension, movement disorders, myelopathy, 
epilepsy), and psychiatric (acute confusional states, anxiety disor-
der, cognitive dysfunction, affective disorder). The peripheral syn-
dromes are acute inflammatory demyelinating polyradiculopathy 
(Guillain-Barre syndrome), autonomic disorder, mononeuropathy 
(single/multiplex), myasthenia gravis, cranial neuropathy, plex-
opathy, and polyneuropathy. The most common syndromes which 
require neuroimaging studies are headache, cerebrovascular disease, 
epilepsy and cognitive dysfunction8,15, and also represent four out 
of five globally most prevalent NPSLE syndromes, as demonstrated 
by an extensive, recent meta-analysis7. NPSLE is also divided into 
primary, attributed to SLE specific mechanisms, and secondary, 
consequence of infections, drugs or metabolic errors, although 
there are no definitive methods to differentiate between them6,10.
In spite of outstanding advances and increasing efforts into research, 
the physiopathology of NPSLE remains still unclear. Neural and vas-
cular injuries related to antibodies and cytokines were incriminated 
in active NPSLE. The pathological substrate of NPSLE consists 
of microangiopathic disease (the most frequent neuropathological 
finding, typically multifocal, due to intimal hyperplasia, erythro-
cytes extravasation and fibrin thrombi), macroscopic infarcts (par-
tially explained by secondary coagulopathy due to antiphospholipid 
antibodies or by embolic phenomena due to Libman–Sacks endo-
carditis), accelerated atherosclerosis (partially due to steroid treat-
ment, vasculitis and microhemorrhages), direct immune mediated 
alterations, demyelination and microembolisms5,16–19.
Magnetic resonance imaging (MRI) is the gold standard for study-
ing the brain in SLE. The role of other imaging modalities such as 
computer tomography (CT) is essentially to rule out acute compli-
cations such as hemorrhage or large infarcts, or to assess differ-
ential diagnoses5,20,21. The large spectrum of clinical presentations, 
laboratory and pathological findings in NPSLE made the neurora-
diological findings nonspecific, a wide range of abnormalities being 
described8,22. The most frequently reported findings with conven-
tional MRI in large series of NPSLE were multiple small white-
matter lesions (30–75%) and cortical atrophy (15–20%), although 
there is a large percentage of patients (25–60%) with normal MRI 
scan8,11,23,24. Advanced MRI techniques such diffusion-tensor, 
magnetization-transfer and volumetric studies, which give micro-
structural and functional information, could provide evidence of 
subtle brain changes that allow better understanding of the NPSLE 
mechanisms. Furthermore, the correlation of the neuroradiologi-
cal, clinical and immunological biomarkers could give insights 
into the pathophysiology of the disease. The present review aims to 
describe the neuroimaging findings in conventional and advanced 
MRI imaging in NPSLE patients, and their importance from a 
practical point of view.
Conventional MRI neuroimaging findings
Around 50% of the NPSLE patients had normal MRI, especially in 
diffuse syndromes such as headache, mood disorder, and psychi-
atric disease8. In the other half of the patients, the most common 
neuroimaging findings can be classified as vascular diseases (small 
or large vessel disease), and inflammatory-type lesions (Table 1).
Vascular disease, although nonspecific and in many forms of 
manifestation, is the hallmark of NPSLE8. Vascular lesions are ill-
defined hyperintensities on T2, and moderately hypointense or iso-
intense on T1. Large vessel disease refers to large infarcts, which 
have medium-to-large size, are roughly wedge-shaped, occur with a 
vascular territory distribution, and involve both grey and white matter 
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(Figure 1a). With diffusion-weighted imaging (DWI) it is possible to 
determine if they are in the acute, subacute or chronic stage, including 
silent infarcts. Large vessel infarcts are one of the most debilitating 
complications of NPSLE, and are found in 10–15% of patients and at 
a mean age of 35–40 years8,23,25,26. When infarcts occur in NPSLE, a 
tendency to multiplicity was noticed, which is translated into a high 
recurrence of ischemic events8. Middle cerebral artery territory is 
mainly involved, as in the general population8. Many authors associ-
ated antiphospholipid antibodies with infarcts and reported a stroke 
recurrence of around 50% when these antibodies were present23,25,27. 
Stroke was also more commonly observed in the presence of hyper-
tension, cerebrovascular syndrome and seizures5.
Small vessel disease is typically represented by lesions smaller than 
1 cm, which follow the distribution of the white matter (periven-
tricular, deep, subcortical) (Figure 1b). Recently, the definitions of 
neuroimaging findings of small vessel disease have been established 
and consist in white-matter hyperintensities, recent small subcorti-
cal infarcts, lacunes, microbleeds and brain atrophy28. White-matter 
hyperintensities (WMH) are the most widespread type of small ves-
sel disease seen in SLE patients, and represents the collective term 
referring to small T2-hyperintensities including the white matter, 
basal ganglia, cerebellum and brainstem28. They are characterized as 
hyperintense on T2 and FLAIR sequences, without cavitation, gen-
erally small and ill-defined28,29. The differential diagnosis of WMH is 
very wide, being associated with many conditions including ageing, 
dyslipidemia, diabetes, hypertension, heart diseases and migraine28. 
However, many previous reports already proved increased frequency 
of WMH in SLE and NPSLE22,30–37. WMH had been shown to involve 
preferentially the frontal and parietal lobes, consistent with an ante-
rior to posterior gradient, similar to other causes of WMH, but dif-
ferent from inflammatory demyelinating etiologies such as multiple 
Table 1. Magnetic resonance imaging classification proposed for brain abnormalities in 
patients with neuropsychiatric lupus.
Abnormalities type
Inflammatory-like lesions 
          Location: supratentorial/infratentorial 
          Contrast-enhancement 
          Diffusion restriction 
Large vessel disease 
          Single/multiple 
          Acute/subacute/chronic 
          Vascular territory 
Small vessel disease28 
          White matter hyperintensities29 
                    Location: frontal, parieto-occipital, temporal, basal ganglia, infratentorial 
                    Degree of involvement: focal lesions, beginning confluence, diffuse involvement 
                    Lesion burden: <5 lesions (low lesion burden); 5–25 (intermediate lesion burden); 
                    >25 (high lesion burden) 
          Lacunes 
          Recent small subcortical infarcts 
          Microbleeds 
          Brain atrophy (GCA scale)49
Abbreviations: GCA-Global Cortical Atrophy scale.
a b
Figure 1a–b. Coronal FLAIR images demonstrate both large and small vessel disease. 1a Large hyperintense cortico-subcortical area 
consistent with a chronic stroke involving the right middle cerebral artery territory. 1b Focal bilateral white matter hyperintensities reflecting 
small vessel disease. Figure origin: Department of Radiology, Hospital Clinic Barcelona.
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sclerosis8,38. In a quantitative cerebral MRI assessment, Appenzeller 
et al.35 showed that age, duration of neuropsychiatric manifestations 
and cumulative corticosteroid dosage were independent predictors 
for WMH in SLE. In a recent study in patients with newly diag-
nosed SLE, WMH were found in 8% of the patients39. Neverthe-
less, these lesions were observed more frequently in NPSLE when 
compared with SLE without neuropsychiatric manifestations, with 
average ranges from 40 to 60%8,11,20,35,37,39,40. WMH were associ-
ated with cerebrovascular disease, cognitive dysfunction, seizures, 
antiphospholipid antibodies, low complements (C3, C4, CH50), 
age, disease duration, and cumulative corticosteroid dose8,35. Pre-
vious reports demonstrated a significant association between both 
NPSLE activity (Neuro-SLEDAI) and injury (Neuro-SLICC) scores 
with the number of WMH (high lesion burden)11,35,37,39,41. Further-
more, new lesions were noticed during onset of new neuropsychiat-
ric manifestations, and resolution of lesions was found with clinical 
improvement26,42,43. Quantitative methods are increasingly proposed 
for the quantification and follow-up of the WMH in NPSLE, as they 
can function as an independent predictor for the NPSLE activity and 
injury, holding promise to open a new line of follow-up of NPSLE 
patients and their response to therapy, similar to the monitoring of 
multiple sclerosis33,35,39.
Recent small subcortical infarcts, commonly known as lacunar inf-
arcts, are infarctions in the territory of perforating arterioles, of less 
than 20 mm in its maximum diameter in the axial plane, with imaging 
signs or clinical symptoms consistent with a lesion occurring in the 
previous few weeks28. Their natural evolution is into lacunes, WMH 
without cavitation, or they might disappear44. Old lacunar infarcts 
(lacunes) must be differentiated from perivascular (Virchow-Robin) 
spaces, which generally are smaller, located mostly around the 
anterior commissure and usually appear linear when imaged paral-
lel to the course of the vessel. Lacunes were commonly described in 
elderly, asymptomatic individuals, in the presence of hypertension, 
and were related to dementia, gait impairment and increased risk 
of stroke28. Very few studies evaluated lacunes in NPSLE and they 
were found with a prevalence of 11.5–16%, higher than in the gen-
eral population8,11. Cerebral microbleeds are small (usually 2–5 mm, 
but up to 10 mm) round or oval areas of signal void with associ-
ated blooming on paramagnetic-sensitive sequences such as T2*-
weighted gradient recalled echo (GRE) or susceptibility-weighted 
images (SWI). Microscopically, hemosiderin-laden macrophages in 
perivascular tissue are seen, indicating vascular leakage of blood 
cells, related to bleeding-prone microangiopathy. In the general pop-
ulation, microbleeds are usually located in the cortico-subcortical 
junction, deep grey and white matter, brainstem and cerebellum. 
They were associated with hypertension, amyloid angiopathy, cog-
nitive impairment and Alzheimer disease45,46. In NPSLE, microb-
leeds were found in 14.5% of the patients on GRE/SWI sequences, 
and were correlated with lupus anticoagulant (antiphospholipid 
antibodies) and cerebrovascular syndrome8.
Cortical atrophy is seen as generalized enlargement of peripheral 
cerebrospinal fluid spaces and is best evaluated on volumetric 3D-T1 
or FLAIR images. In the general population, age related atrophic 
changes are small prior to age 50 years, as proved by a large study47 
or, similarly, by another underlying that brain volumes in females 
remained stable over a span of 15 to 69 years of age48. There are 
different scales to unify the radiological language, one of the most 
known being the global cortical atrophy scale (GCA)49. GCA evalu-
ation at the onset of NPSLE observed cortical atrophy in 18.5% of 
the subjects, most commonly in a mild grade, and at a mean age of 
42.5 years8. Brain atrophy occurs more frequently in the presence 
of other radiological manifestations consistent with small vessel 
disease, such as WMH, high lesion burden, lacunes and microb-
leeds8. Brain atrophy was also correlated with lupus anticoagulant, 
low complement, longer disease duration, cognitive dysfunction 
and cerebrovascular disease23,37. Many authors suggested that the 
atrophy might be the result of the prednisone use37,50, while others 
found no association31,39,51,52, which suggests that additional mecha-
nisms, probably related to NPSLE itself, seem to be involved53–56.
Less frequently, some NPSLE patients present inflammatory-type 
lesions which were described as ill defined, hyperintense on T2 and 
FLAIR, involving the grey and white matter, generally medium 
or large-sized, some of them with contrast enhancement or diffu-
sion restriction, without vascular territory distribution nor clinical 
and radiological features of infarcts, which usually resolves after 
aggressive corticosteroid treatment. They were reported in 5–10% 
of patients, and were correlated with low complement levels, indi-
cating an immunological damage related to antibodies and cytokines 
and supporting the immunological pathogenesis of NPSLE6. Yet 
rarely present, findings related to cerebral vasculitis were described, 
when angiography exams (MRI or conventional) could show focal 
beadings and narrowings of large and small arteries16,57–60.
Myelitis, a type of inflammatory involvement of the central nervous 
system, is one of the most debilitating complications of NPSLE and 
occurs in 1–5% of SLE patients. It usually develops early in the 
evolution of the disease and associates a worse outcome. In 39% 
of the patients with SLE related myelopathy, it constitutes the pre-
senting symptom of SLE, and in another 42% it occurs during the 
first 5 years after the diagnosis. The most described MRI pattern in 
SLE myelitis is consistent with transverse myelitis: commonly long 
affected segment, more than 2–3 vertebral bodies in length and with 
injury of both halves of the cord (Figure 2). Transverse myelitis 
associates a variable swelling and focal enlargement. Enhancement 
is usually absent or poor, patchy in the most active presentations. 
The outcome of SLE myelitis is variable, ranging from complete 
recovery to severe disability, but the injury is typically much less 
extensive on follow up MRI10,61.
Advanced MRI techniques
Up to 40–50% of NPSLE patients had no brain abnormalities on con-
ventional MRI8,11,31,33,36,62. Nonetheless, advanced MRI sequences in 
NPSLE demonstrated underlying abnormalities in normal appearing 
white and grey matter, which shows the limitations of conventional 
sequences52,63,64. Recent studies used advanced MRI techniques in 
the analysis of NPSLE, as the assessment of tissue-specific atrophy 
by morphometric methods38,52,65, diffusion-tensor imaging52,64,66,67, 
magnetization transfer imaging52,66,67, magnetic resonance spectros-
copy67,68 and perfusion MRI. The use of nanoparticles for molecu-
lar MRI is another new technique with potential interest in SLE, 
although its applications in NPSLE have not yet been studied69.
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Voxel based morphometry (VBM) is a technique which allows the 
assessment of the focal differences in brain anatomy and, there-
fore, the assessment of tissue-specific atrophy. The volume in every 
voxel is compared across the brain, and VBM is frequently per-
formed for examining differences between populations, although it 
can also be used to assess asymmetries between brain hemispheres. 
Morphometric studies showed that decreased whole brain volume 
with increased lateral ventricle volume and both global gray mat-
ter and white matter atrophy are present in SLE patients compared 
to healthy controls70. Moreover, it was demonstrated that atrophy 
evolved over a short period of time52,68,71. A number of publications 
found that selective cortical atrophy was the tissue specific atrophy 
measure with best correlation with the presence of NPSLE, and sug-
gested that cortical atrophy is more important for mediating brain 
damage in NPSLE patients than the white matter lesions52,71. From a 
practical point of view, the macroscopic damage of the cortical gray 
matter might be more important for identifying NPSLE patients 
than the micro- or macrostructural damage in the white matter52,71, 
yet it was reported an association of NPSLE with both cortical and 
central atrophy52,65,72. Some authors compared cohorts of NPSLE 
with SLE and controls. The NPSLE group exhibited decreased cor-
tical thickness in left frontal and parietal lobes as well as in right 
parietal and occipital lobes compared to controls. Both SLE and 
NPSLE groups exhibited comparable thinning in frontal and tem-
poral lobes73. Automated morphometric methods were also used for 
segmenting white matter lesions in patients with SLE, which could 
give a more precise quantification of the focal injuries74.
Diffusion-tensor imaging (DTI) is based on the measurement of 
water diffusion through cellular compartments, and was demon-
strated to provide better resolution than conventional sequences 
regarding white matter microstructure (Figure 3a–b)75,76. Compared 
to more isotropic movement of water in gray matter, the diffusion 
Figure  2.  Sagittal  T2-weighted  image  shows  an  extensive 
hyperintensity involving the medulla oblongata and the cervico-
toracic  cord,  compatible  with  a  myelitis  pattern. Figure origin: 
Department of Radiology, Hospital Clinic Barcelona.
a b
Figure 3a–b. Axial maps of fractional anisotropy (FA). 3a Normal FA shows the integrity and directionality of the white matter fibers (red: 
right-left, green: anterior-posterior, blue: craneo-caudal). 3b Altered (low) FA seen as loss of the normal colors of the left corticospinal tract in 
the internal capsule and of the left longitudinal fasciculus related to ischemic infarct of the territory of the left middle cerebral artery (arrows) 
in a patient with neuropsychiatric lupus and stroke. Figure origin: Department of Radiology, Hospital Clinic Barcelona.
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in white matter presents higher anisotropy, with preferential dif-
fusion along the length of the axon. This anisotropy is due to the 
well-structured axonal membranes and their myelin sheaths. The 
diffusion can be quantified by the following parameters: apparent 
diffusion coefficient (ADC), fractional anisotropy (FA), mean dif-
fusivity (MD), radial diffusivity (RD) and axial diffusivity (AD). 
FA is a measure of myelination and axonal integrity, and MD a 
measure of molecular motion. High FA and low MD suggest greater 
myelination and axonal integrity. Previous studies found changes 
in various DTI indices in SLE and NPSLE patients, in relation to 
important microscopic injury of the white matter77. In patients with 
SLE, white matter injury in frontal lobes, corpus callosum, and tha-
lamus has been found68,78–80. FA values were reported to be lower 
and MD values to be higher in the brain of NPSLE patients than 
in healthy controls. Increased AD of white matter was also corre-
lated with NPSLE when compared to healthy populations. It was 
suggested that the underlying pathological substrate of white mat-
ter changes in NPSLE may be the selective axonal damage52,66,71. A 
localized injury of white matter tracts was also demonstrated in the 
limbic system, internal capsule, corpus callosum, forceps major and 
corona radiata64,67,79,81,82. Very recent publications underline the role 
of DTI as an imaging biomarker of NPSLE83.
Magnetization transfer imaging (MTI) is based on the interaction 
between free water protons and bound protons. The differences in 
the proton mobility in various macromolecules and tissues are used 
to generate differences in image signal. Thus, MTI is used to gener-
ate contrast, and it has a variety of clinical applications. Volumet-
ric MTI was used to quantify cerebral lesions in different diseases, 
mainly in multiple sclerosis. Bosma et al.84 compared MTI histogram 
parameters in 5 groups of patients: active NPSLE, chronic NPSLE, 
SLE without NPSLE, multiple sclerosis, and normal control sub-
jects. The magnetization transfer ratio histograms in the group of 
SLE without NPSLE and the group of healthy controls were simi-
lar, whereas those in chronic NPSLE and multiple sclerosis groups 
were flatter. The active NPSLE group showed also a flattening of 
the histograms, but with a higher magnetization transfer ratio. This 
suggests that MTI could be able to differentiate active NPSLE. It 
is also believed that MTI might be a good method for monitoring 
treatment trials in NPSLE84. A report combining MTI with mag-
netic resonance spectroscopy (MRS) found correlation between 
brain atrophy and MRS markers of axonal and myelin damage67. 
Studies combining MTI with DWI, MRS and T2 relaxometry data 
in NPSLE suggest a common pathogenesis in NPSLE in spite of the 
many differences in the neuropsychiatric presentation52,66.
MRS allows the analysis of brain metabolites. Different proton 
groups have different magnetic fields in relation to their valence 
electrons. As a result, they resonate at different frequencies of the 
magnetic field, which can be demonstrated by MRS, as peaks that 
correspond to different metabolites. N-acetylaspartate (NAA) is 
one of the main markers assessed on MRS and is found in higher 
concentrations in neurons, thus it is a marker of neuronal viability. 
Glutamate, a non-essential amino acid, is the most important excita-
tory neurotransmitter, and prolonged neuron excitation by glutamate 
can be toxic to neurons. NAA and glutamine-glutamate changes 
were demonstrated in normal-appearing brain in SLE patients, 
before neurologic and imaging manifestations became apparent, 
which suggests that these markers might predict the early cerebral 
involvement of SLE85. Lower NAA ratios were also reported in both 
SLE and NPSLE patients63, and increased myo-inositol, a marker of 
gliosis, was suggested as a marker of poor prognosis in NPSLE86. 
The demonstration of the uptake of specific metabolites might in 
the future be closely associated with neuronal injury in NPSLE.
Perfusion imaging such as done with single-photon emission com-
puted tomography (SPECT), positron emission tomography (PET) 
and MRI could reveal abnormalities in SLE patients. There are 
three techniques of perfusion MRI, based on the administration of 
gadolinium (dynamic susceptibility contrast imaging and dynamic 
contrast enhanced imaging), or without contrast administration 
(arterial spin labeled imaging). The main parameters derived from 
them are mean transit time (MTT), time to peak (TTP), cerebral 
blood flow (CBF) and cerebral blood volume (CBV). The defined 
pathological patterns are hypoperfusion (high MTT/TTP, low CBF/
CBV) and hyperperfusion (low TTP/MTT, high CBV/CBF)87. Few 
prospective studies analyzed brain perfusion in SLE patients. Some 
authors showed that perfusion in SLE patients was not different 
from healthy controls88, while others reported a pattern of hypop-
erfusion in both SLE and NPSLE63, or even hyperperfusion in the 
posterior cingulate gyrus in patients with active disease89.
Overall, advanced MRI techniques seem to be able to detect micro-
structural brain damage in a very early stage when not visible on 
conventional sequences. There could be a temporal dissociation 
between the detection of damage with these sequences and its trans-
lation to significant abnormalities on conventional MRI. Advanced 
MRI is also expected to help to better understand the underlying 
pathological substrate of cerebral damage in NPSLE. However, the 
role of advanced MRI techniques in patients with SLE is yet in 
its infancy and needs to be further investigated. Future longitudi-
nal studies should determine whether early changes of the white 
and gray matter in NPSLE patients may involve a higher degree 
of tissue-specific brain atrophy over time and to what extent it 
would be possible to monitor disease progression and response to 
therapy.
Looking at all sides of the argument, it is questionable what patients 
and when should be referred for brain MRI and what is the role of 
MRI in the clinical management of NPSLE. Syndromes such as 
cerebrovascular disease, cognitive dysfunction, seizures and mye-
lopathy, as well as the focal symptomatology, were often related 
with radiological abnormalities, and require to be comprehen-
sively studied; additional sequences such as DWI, GRE/SWI and 
contrast-enhanced should be included when MRI is performed in 
these patients. Conversely, MRI is more likely to be unremarkable 
in some other syndromes such as headache, psychosis and, gener-
ally, diffuse neurological presentations rather than focal ones. Addi-
tionally, the status of antiphospholipid antibodies, complement and 
disease activity plays an important role. Therefore, in the current 
settings, the decision of when imaging a patient remains probably 
best reached through a case-based clinical judgment.
The other side of the argument of MRI in NPSLE regards ruling 
out other causes of neuropsychiatric manifestations rather than 
diagnosing NPSLE. Despite MRI being the imaging modality of 
choice and despite significant recent advances in this field, there are 
neither diagnostic nor specific radiological findings for NPSLE, 
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meaning that MRI cannot confirm nor exclude the diagnosis of 
NPSLE. Nevertheless, in the absence of alternative diagnoses when 
imaging a SLE patient, some patterns may be proposed: stroke in 
young patients, more than one infarct, association between large 
and small vessel disease, high lesion burden at young age and pre-
mature cortical atrophy. All these in a subject meeting criteria for 
SLE and without other risk factors, probably could suggest either 
the presence or a possible development of NPSLE in the following 
period.
In conclusion, MRI is crucial for both supporting the diagnosis of 
NPSLE and for ruling out alternative diagnoses. A complex diag-
nostic algorithm including neurophysiologic studies, laboratory 
tests and MRI is probably the best clinical approach. The multi-
modal MRI approach including conventional and advanced tech-
niques may be an important tool for monitoring the disease activity, 
progression and treatment response, and may provide fundamental 
insights into the pathological substrate. To make this possible, a 
common radiological terminology is a first requirement.
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This review is well written and give us a comprehensive updating on magnetic resonance imaging in
NPSLE. 
Only few minor suggestions:
Introduction - Authors say that "reliable methods for diagnosing NPSLE are also unknown...". This
is essentially true, but they could quote the recent contribution by  dealingBortoluzzi . (2015),et al
with the development of a new algorithm for attribution of NP events in SLE.
 
Conventional MRI, page 2 - "DWI sequences". Please specify the meaning of DWI.
 
Conventional MRI, page 3 - "total corticosteroid". Cumulative is better.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
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,  Murray B. Urowitz Zahi Touma
Lupus Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital,
University of Toronto, Toronto, ON, Canada
Sarbu  review the utility of MRI imaging in neuropsychiatric lupus (NPL) both what is available todayet al.
in routine care and for research purposes and what might become useful in clinical care in the future. In
NPL clinicians are interested in three major questions. First, is there evidence of NPL at any time in the
past; secondly, is there evidence of active NPL currently; and thirdly can you demonstrate change over
time with or without treatment in NPL.
In terms of the first question Sarbu review the conventional MRI findings in the cortical, subcorticalet al. 
and spinal cord regions. However the nature of the morphologic changes is non specific and many could
be compatible with hypertension, amyloid, Alzheimers etc. and thus may not be helpful to the clinician.
Even the advanced techniques (not universally available) measuring brain volume and composition are
not specific for SLE.
In terms of the second question Sarbu review Magnetic Resonance Spectroscopy (MRS) whichet al. 
allows the analysis of brain metabolites. The demonstration of the uptake of specific metabolites might in
the future be associated with neuron excitation but no studies are available in NPL.
Perfusion imaging such as also done with SPECT and PET scanning can reveal areas of hyper or
hypoperfusion but thus far no studies demonstrating active NPL which could change over time exists.
In conclusion, this article is a good review of what currently exists and what may be developed over time
with MRI imaging. The authors conclude that further clinical association studies with conventional and
advanced techniques are required before MRI imaging will become the standard to understand the
mechanism, diagnosis and monitoring of NPL.
We have read this submission. We believe that we have an appropriate level of expertise to
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We have read this submission. We believe that we have an appropriate level of expertise to
confirm that it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
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 Fabiola Atzeni
Rheumatology Unit, Luigi Sacco University Hospital, Milan, Italy
Title and Abstract: The title is quite generic and perhaps the description of old and new techniques
should be emphasized.
: Design, methods and analysis are well explained and appropriate, however the use ofArticle content
nanoparticles (e.g. SPIONS) should be mentioned among the new MRI techniques. 
: The conclusions underline the need for MRI imaging in symptomatic neuropsychiatric SLE,Conclusions
although a standardized consensus still lacks. It should be more evidenced, however, the utility of a
complex diagnostic algorithm, including neurophysiologic study of the brain or lab tests, beyond the solely
use of MRI.
: Methods and indications to a specific procedure are well described ; MRI findings are reportedData
according to pathologic or clinical pictures.
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